Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Guided Posters

Thyroid - Translational & Clinical

ea0041gp199 | Thyroid - Translational & Clinical | ECE2016

Does maternal thyroid autoimmunity predict adverse pregnancy outcomes?

Sastre-Marcos Julia , Val-Zaballos Florentino , Ruiz-Gines Miguel Angel , Olivar-Azuara Monica , Agudo-Macazaga Mercedes , Fontelles-Alcover Roser , Maldonado Dolores , Lopez-Lopez Jose

Background: Previous studies of association between maternal thyroid autoimmunity and adverse pregnancy outcomes have produced inconsistent results.Objective: To examine whether thyroid autoimmunity detected at first trimester screening is predictive of a range of adverse obstetric and fetal outcomes.Patients and methods: We studied 438 women with singleton pregnancies who underwent first trimester screening test between June and J...

ea0041gp200 | Thyroid - Translational & Clinical | ECE2016

Betatrophin level in Hashimoto thyreoiditis

Poplawska-Kita Anna , Siewko Katarzyna , Kosciuszko-Zdrodowska Maria , Lipinska Danuta , Milewski Robert , Poplawski Lukasz , Szelachowska Malgorzata , Gorska Maria

Aim: Clinical studies in Hashimoto thyroditis (HT) confirm, that even a minor thyroid dysfunction is related to significant changes in body mass. Betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, is a novel protein predominantly expressed in human liver and adipose tissue. Stimulators of betatrophin, such as thyroid hormones are usually relevant to energy expenditure or thermogenesis. The mechanisms of action of betatrophin are still unknown. In the present study ...

ea0041gp201 | Thyroid - Translational & Clinical | ECE2016

The importance of maternal thyroid for the placental function

Barjaktarovic Mirjana , Korevaar Tim I M , Jaddoe Vincent W V , de Rijke Yolanda B , Visser Theo J , Steegers Eric P , Peeters Robin P

Introduction: Maternal thyroid hormone during early pregnancy is important for proper fetal growth and development. Thyroid hormone receptors are widely expressed in placental tissue. Interestingly, thyroid dysfunction and suboptimal placental function have both been associated with pregnancy complications including preeclampsia, premature delivery and fetal growth restriction. First, we studied the association of the maternal thyroid and placental function and second, we inve...

ea0041gp202 | Thyroid - Translational & Clinical | ECE2016

Does mitotane influence free thyroid hormones levels? A possible explanation in vivo and in vitro

Blanchet Benoit , Clemence Leguy Marie , Le Monnier Aude , Habbas Halim , Claude Menet Marie , Groussin Lionel , Guibourdenche Jean

Mitotane (o.p’DDD, Lysodren) is used to treat adrenortical carcinoma and Cushing syndromes. It is catabolised into o.p’DDA and o.p’DDE. It is lowly protein-bound but its tropism for lipids is high. It has multiple side effects on the digestive gut increasing alkaline phosphatases and cholesterol. Patients treated with mitotane have been described as having decreased FT4 levels without any signs of hypothyroidism. We wanted to know whether this is due to an analy...

ea0041gp203 | Thyroid - Translational & Clinical | ECE2016

Repeating FNA in AUS/FLUS – is it necessary?

Alves Rafael Ana , Rodrigues Marques Ricardo , Sofia Silva Silvia , Viana Fernandes Luis

Background: The review of the Bethesda System Classification has brought some challenge to the clinical role of category III lesions. Repeating fine-needle aspiration (FNA) is time-consuming, painful, brings additional cost and sometimes does not change the clinical decision. Our aim was to prove if there is true benefit in repeating FNA.Methods: Retrospective review of 4549 thyroid FNAs between January 2012 and June 2015, from which 671 classified as AU...

ea0041gp204 | Thyroid - Translational & Clinical | ECE2016

Selenium supplementation and autoantibody titers in Graves’ disease

Faltado, Marc Antonio Jr , Yu Gregory , Rosario Acampado Laura

Background: Selenium (Se), a trace mineral with anti-oxidative properties, has been proposed to be potentially beneficial in patients with Graves’ disease (GD), especially those with active Graves’ ophthalmopathy (GO).Methods: Trials evaluating the efficacy of Se among non-pregnant adult GD patients with active GO, versus either placebo or an alternative drug, and on top of standard therapy, were included. A literature search was performed by t...

ea0041gp205 | Thyroid - Translational & Clinical | ECE2016

One in four patients with adequately treated primary hypothyroidism continue to be symptomatic and persisting symptoms related to ongoing thyroid auto-immunity

Jacob Jubbin , Sebastain Ivy , John Mary

Background: A significant percentage of patients with adequately replaced primary hypothyroidism (PH) continue to be symptomatic. Some of these persisting symptoms maybe attributed to non-restoration of neurocognitive functions and psychological well-being.Objectives: To estimate the prevalence of persisting hypothyroid symptoms in patients with PH on biochemically adequate replacement therapy. To correlate persistent symptoms with thyroid hormone levels...

ea0041gp206 | Thyroid - Translational & Clinical | ECE2016

FREND™ Thyroid Duo: a new way of helping patients with subclinical thyroid dysfunction

Han Sunmi , Lee Hyejin , Seong Jihyun , Jeong Je-Sik , Lee Changseop

Introduction: Subclinical thyroid dysfunction is defined as an abnormal serum thyroid-stimulating hormone (TSH) level and free thyroxine (FT4) and triiodothyronin (T3) levels within their reference ranges. The prevalence of subclinical thyroid dysfunction has increased, especially in women older than 60 years. There is good evidence that subclinical hypothyroidism is associated with progression to overt disease, so screening is recommended for high-risk populations. FREND&#153...

ea0041gp207 | Thyroid - Translational & Clinical | ECE2016

Predictive factors of outcomes in radioiodine treatment for Graves’ disease

Cardoso Luis , Rodrigues Dircea , Silva Monica , Vicente Nuno , Guelho Daniela , Martins Diana , Oliveira Diana , Lages Adriana , Ventura Mara , Costa Gracinda , Pedroso Lima Joao , Carrilho Francisco

Introduction: Radioiodine (131I, RAI) is a safe and effective option for the treatment of Graves’ disease (GD). However, approximately 20% of RAI treated patients will have persistent disease or will relapse after the first treatment. Our aim was to identify the factors influencing the outcomes in RAI treatment for GD.Methods: We analysed 143 DG patients (116 women) treated with RAI between October 2002 and April 2014 and ≥12 months...

ea0041gp208 | Thyroid - Translational & Clinical | ECE2016

Thyroid hormone profile after the single dose of iodine-containing contrast agent administration during coronary angiography-prospectice study

Rychlik Slawomir , Chmiel Artur , Wierzbicka-Chmiel Joanna , Otremba Lukasz , Kreis Wojciech , Marek Bogdan , Kajdaniuk Dariusz

Introduction: Previous studies suggest close relationship between thyroid morphology and the danger of thyroid hormones (THs) disturbances after high single dose of iodine-containing contrast agent. The aim of the study was to assess the prognostic risk factors which influence on THs after the cardiac catheterization at patient with coronary artery disease (CAD).Methods: One hundred twenty patient (F/M=40/80, 59±11 years old) without recognized prev...